These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Banwell B; Bar-Or A; Arnold DL; Sadovnick D; Narayanan S; McGowan M; O'Mahony J; Magalhaes S; Hanwell H; Vieth R; Tellier R; Vincent T; Disanto G; Ebers G; Wambera K; Connolly MB; Yager J; Mah JK; Booth F; Sebire G; Callen D; Meaney B; Dilenge ME; Lortie A; Pohl D; Doja A; Venketaswaran S; Levin S; Macdonald EA; Meek D; Wood E; Lowry N; Buckley D; Yim C; Awuku M; Cooper P; Grand'maison F; Baird JB; Bhan V; Marrie RA Lancet Neurol; 2011 May; 10(5):436-45. PubMed ID: 21459044 [TBL] [Abstract][Full Text] [Related]
24. Epigenetic changes in neurology: DNA methylation in multiple sclerosis. Iridoy Zulet M; Pulido Fontes L; Ayuso Blanco T; Lacruz Bescos F; Mendioroz Iriarte M Neurologia; 2017 Sep; 32(7):463-468. PubMed ID: 25976949 [TBL] [Abstract][Full Text] [Related]
25. Multiple sclerosis: geoepidemiology, genetics and the environment. Milo R; Kahana E Autoimmun Rev; 2010 Mar; 9(5):A387-94. PubMed ID: 19932200 [TBL] [Abstract][Full Text] [Related]
26. The epidemiology of multiple sclerosis: insights to disease pathogenesis. Goodin DS Handb Clin Neurol; 2014; 122():231-66. PubMed ID: 24507521 [TBL] [Abstract][Full Text] [Related]
27. Disease mechanisms in MS: informing tactics to combat MS. Kingwell K Nat Rev Neurol; 2012 Nov; 8(11):589. PubMed ID: 23128361 [No Abstract] [Full Text] [Related]
28. Environmental factors in the development of multiple sclerosis. Michel L Rev Neurol (Paris); 2018 Jun; 174(6):372-377. PubMed ID: 29735167 [TBL] [Abstract][Full Text] [Related]
29. Gender differences in multiple sclerosis epidemiology and treatment response. Magyari M Dan Med J; 2016 Mar; 63(3):. PubMed ID: 26931196 [TBL] [Abstract][Full Text] [Related]
31. Environmental factors and their interactions with risk genotypes in MS susceptibility. Hedström AK; Alfredsson L; Olsson T Curr Opin Neurol; 2016 Jun; 29(3):293-8. PubMed ID: 27035899 [TBL] [Abstract][Full Text] [Related]
32. [Multiple sclerosis and Epstein-Barr virus : new developments and perspectives]. Ruprecht K Nervenarzt; 2008 Apr; 79(4):399-407. PubMed ID: 17713752 [TBL] [Abstract][Full Text] [Related]
33. Epidemiology and natural history of multiple sclerosis: new insights. Kantarci O; Wingerchuk D Curr Opin Neurol; 2006 Jun; 19(3):248-54. PubMed ID: 16702830 [TBL] [Abstract][Full Text] [Related]
34. The epidemiology of multiple sclerosis in Europe. Pugliatti M; Rosati G; Carton H; Riise T; Drulovic J; Vécsei L; Milanov I Eur J Neurol; 2006 Jul; 13(7):700-22. PubMed ID: 16834700 [TBL] [Abstract][Full Text] [Related]
35. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. Karussis D J Autoimmun; 2014; 48-49():134-42. PubMed ID: 24524923 [TBL] [Abstract][Full Text] [Related]
36. Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC). Burrell AM; Handel AE; Ramagopalan SV; Ebers GC; Morahan JM Discov Med; 2011 Mar; 11(58):187-96. PubMed ID: 21447278 [TBL] [Abstract][Full Text] [Related]
38. Diagnostic Criteria, Classification and Treatment Goals in Multiple Sclerosis: The Chronicles of Time and Space. Ntranos A; Lublin F Curr Neurol Neurosci Rep; 2016 Oct; 16(10):90. PubMed ID: 27549391 [TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samples. Salzer J; Nyström M; Hallmans G; Stenlund H; Wadell G; Sundström P Mult Scler; 2013 Oct; 19(12):1587-91. PubMed ID: 23549431 [TBL] [Abstract][Full Text] [Related]
40. Epidemiology and current treatment of multiple sclerosis in Europe today. Pozzilli C; Romano S; Cannoni S J Rehabil Res Dev; 2002; 39(2):175-85. PubMed ID: 12051462 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]